April 9 (Reuters) - Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by Summit Therapeutics' executive Ankur Dhingra. (Reporting by Pritam Biswas in Bengaluru; Editing by Shilpi Majumdar)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.925 USD | +1.68% | +13.90% | +52.30% |
Apr. 11 | Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors | CI |
Apr. 09 | Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed | RE |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
124.2 USD | +1.58% | +4.06% | 19.47B | ||
3.925 USD | +1.68% | +13.90% | 2.71B | ||
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+52.30% | 2.71B | |
-2.62% | 103B | |
+1.53% | 95.28B | |
+1.46% | 22.15B | |
-15.87% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.02% | 16.05B | |
+5.16% | 13.68B | |
+33.86% | 12.17B |
- Stock Market
- Equities
- SMMT Stock
- News Summit Therapeutics Inc.
- Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor